<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240785</url>
  </required_header>
  <id_info>
    <org_study_id>246/2005</org_study_id>
    <nct_id>NCT01240785</nct_id>
  </id_info>
  <brief_title>Metformin Versus Insulin in Gestational Diabetes</brief_title>
  <official_title>Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used
      worldwide in the treatment of type 2 diabetes and also in a few studies on patients with
      gestational diabetes. The investigators aim is to compare insulin and metformin in the
      treatment of gestational diabetes. The investigators hypothesis is that there is no
      difference between insulin and metformin treated mothers in the main outcome criteria (birth
      weight, neonatal complications).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used
      worldwide in the treatment of type 2 diabetes and also in a few studies on patients with
      gestational diabetes. The investigators aim is to compare insulin and metformin in the
      treatment of gestational diabetes. The investigators hypothesis is that there is no
      difference between insulin and metformin treated mothers in the main outcome criteria (birth
      weight, neonatal complications). The study was performed as a randomized controlled trial in
      one center, Turku University hospital using the non-inferiority design in June 2006 -
      December 2010. The final study population consisted of altogether 217 women, of whom 110
      received metformin and 107 insulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birth Weight Per Arm</measure>
    <time_frame>delivery</time_frame>
    <description>birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Induced Hypertension Per Arm</measure>
    <time_frame>up to on the average 40 weeks of gestation</time_frame>
    <description>Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure &gt; 30 mmHg or diastolic blood pressure &gt; 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Weight Gain Per Arm</measure>
    <time_frame>up to on the average 40 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-eclampsia Per Arm</measure>
    <time_frame>up to on the average 40 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of Delivery Per Arm</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Weeks at Delivery Per Arm</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of Delivery Per Arm</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder Dystocia Per Arm</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hypoglycemia Per Arm</measure>
    <time_frame>0-24 h after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hyperbilirubinemia Per Arm</measure>
    <time_frame>0-3 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Score at 5 Min After Delivery Per Arm</measure>
    <time_frame>5 minutes after delivery</time_frame>
    <description>Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonate Transfer to Intensive Care Unit Per Arm</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Outcome at 2 Years Per Arm</measure>
    <time_frame>2 years after birth</time_frame>
    <description>neuropsychological and motor skills testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Diformin retard 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
    <description>subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
    <arm_group_label>insulin</arm_group_label>
    <other_name>Protaphane</other_name>
    <other_name>Humalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mothers with gestational diabetes who had at least twice plasma glucose at fasting &gt;
             5.4 mmol/L and/or 1 hour postprandial value &gt; 7.7 mmol/L at 24 to 32 gestational weeks

        Exclusion Criteria:

          1. Fasting glucose &gt; 7.0 mmol/L or 1 hour postprandial plasma glucose &gt; 11.0 mmol/L or
             Glycosylated hemoglobin A1c (HbA1c) &gt; 7.0%

          2. Renal, hepatic or cardiac failure

          3. Pregestational use of metformin

          4. Pregnancy with multiple fetuses
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tapani RÃ¶nnemaa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Chief Physician</affiliation>
  </overall_official>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <results_first_submitted>December 4, 2013</results_first_submitted>
  <results_first_submitted_qc>November 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>November 21, 2014</last_update_submitted>
  <last_update_submitted_qc>November 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Tapani RÃ¶nnemaa</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>gestational diabetes</keyword>
  <keyword>metformin</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin Arm</title>
        </group>
        <group group_id="P2">
          <title>Insulin</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110">110 women completed in the metformin arm and 107 women completed in the insulin arm.</participants>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
        </group>
        <group group_id="B2">
          <title>Insulin</title>
          <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="217"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="5.0"/>
                    <measurement group_id="B2" value="32.1" spread="5.4"/>
                    <measurement group_id="B3" value="32.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Birth Weight Per Arm</title>
        <description>birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies</description>
        <time_frame>delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight Per Arm</title>
          <description>birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3604" spread="488"/>
                    <measurement group_id="O2" value="3589" spread="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Induced Hypertension Per Arm</title>
        <description>Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure &gt; 30 mmHg or diastolic blood pressure &gt; 15 mmHg</description>
        <time_frame>up to on the average 40 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Induced Hypertension Per Arm</title>
          <description>Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure &gt; 30 mmHg or diastolic blood pressure &gt; 15 mmHg</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Weight Gain Per Arm</title>
        <time_frame>up to on the average 40 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Weight Gain Per Arm</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="5.3"/>
                    <measurement group_id="O2" value="7.9" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-eclampsia Per Arm</title>
        <time_frame>up to on the average 40 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-eclampsia Per Arm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mode of Delivery Per Arm</title>
        <time_frame>delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Mode of Delivery Per Arm</title>
          <units>no of cesarean section</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Weeks at Delivery Per Arm</title>
        <time_frame>delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Weeks at Delivery Per Arm</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="1.4"/>
                    <measurement group_id="O2" value="39.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction of Delivery Per Arm</title>
        <time_frame>delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Induction of Delivery Per Arm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shoulder Dystocia Per Arm</title>
        <time_frame>delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Shoulder Dystocia Per Arm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hypoglycemia Per Arm</title>
        <time_frame>0-24 h after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hypoglycemia Per Arm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hyperbilirubinemia Per Arm</title>
        <time_frame>0-3 days after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hyperbilirubinemia Per Arm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apgar Score at 5 Min After Delivery Per Arm</title>
        <description>Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome</description>
        <time_frame>5 minutes after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Apgar Score at 5 Min After Delivery Per Arm</title>
          <description>Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.3"/>
                    <measurement group_id="O2" value="8.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonate Transfer to Intensive Care Unit Per Arm</title>
        <time_frame>0-5 days after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Neonate Transfer to Intensive Care Unit Per Arm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Child Outcome at 2 Years Per Arm</title>
        <description>neuropsychological and motor skills testing</description>
        <time_frame>2 years after birth</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Fetal cardiac function evaluated with ultrasound and cardiotokography</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily</description>
        </group>
        <group group_id="E2">
          <title>Insulin</title>
          <description>insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>fetal death</sub_title>
                <description>Fetal death at 39 weeks due to umbilical cord complication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Kristiina Tertti</name_or_title>
      <organization>Department of Obstetrics and Gynecology, Turku University Central Hospital</organization>
      <phone>+358 2 3130000</phone>
      <email>kristiina.tertti@tyks.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

